GlaxoSmithKline: tuberculosis vaccine shows promise in trial
(CercleFinance.com) - A GlaxoSmithKline candidate vaccine has produced a sustained level of protection against active pulmonary tuberculosis, the British drugmaker said on Tuesday.
GSK's M72/AS01E has significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults with latent tuberculosis infection, the company said.
These results demonstrate an overall vaccine efficacy of 50% for a period of three years after vaccination, it added.
The trial was conducted in Kenya, South Africa and Zambia and involved 3,573 HIV-negative adults aged from 18 to 50.
Tuberculosis is the leading cause of death through infectious disease worldwide, killing 1.5 million people in 2018.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
GSK's M72/AS01E has significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults with latent tuberculosis infection, the company said.
These results demonstrate an overall vaccine efficacy of 50% for a period of three years after vaccination, it added.
The trial was conducted in Kenya, South Africa and Zambia and involved 3,573 HIV-negative adults aged from 18 to 50.
Tuberculosis is the leading cause of death through infectious disease worldwide, killing 1.5 million people in 2018.
Copyright (c) 2019 CercleFinance.com. All rights reserved.